{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:01:26Z","timestamp":1790636486165,"version":"4.1.0"},"reference-count":236,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Public Health Agency of Canada\/National Microbiology Laboratory"},{"name":"Foundation of the McGill University Health Centre"},{"name":"Research Institute of the McGill University Health Centre"},{"name":"R. Howard Webster Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Vaccines against parasites have lagged centuries behind those against viral and bacterial infections, despite the devastating morbidity and widespread effects of parasitic diseases across the globe. One of the greatest hurdles to parasite vaccine development has been the lack of vaccine strategies able to elicit the complex and multifaceted immune responses needed to abrogate parasitic persistence. Viral vectors, especially adenovirus (AdV) vectors, have emerged as a potential solution for complex disease targets, including HIV, tuberculosis, and parasitic diseases, to name a few. AdVs are highly immunogenic and are uniquely able to drive CD8+ T cell responses, which are known to be correlates of immunity in infections with most protozoan and some helminthic parasites. This review presents recent developments in AdV-vectored vaccines targeting five major human parasitic diseases: malaria, Chagas disease, schistosomiasis, leishmaniasis, and toxoplasmosis. Many AdV-vectored vaccines have been developed for these diseases, utilizing a wide variety of vectors, antigens, and modes of delivery. AdV-vectored vaccines are a promising approach for the historically challenging target of human parasitic diseases.<\/jats:p>","DOI":"10.3390\/ph16030334","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T05:01:32Z","timestamp":1677042092000},"page":"334","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections"],"prefix":"10.3390","volume":"16","author":[{"given":"Cal","family":"Koger-Pease","sequence":"first","affiliation":[{"name":"Division of Experimental Medicine, McGill University, Montreal, QC H3A 3J1, Canada"},{"name":"Infectious Diseases and Immunity in Global Health (IDIGH) Program, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0874-7251","authenticated-orcid":false,"given":"Dilhan J.","family":"Perera","sequence":"additional","affiliation":[{"name":"Division of Experimental Medicine, McGill University, Montreal, QC H3A 3J1, Canada"},{"name":"Infectious Diseases and Immunity in Global Health (IDIGH) Program, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momar","family":"Ndao","sequence":"additional","affiliation":[{"name":"Division of Experimental Medicine, McGill University, Montreal, QC H3A 3J1, Canada"},{"name":"Infectious Diseases and Immunity in Global Health (IDIGH) Program, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada"},{"name":"Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"National Reference Centre for Parasitology, Research Institute of McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/08998280.2005.11928028","article-title":"Edward Jenner and the History of Smallpox and Vaccination","volume":"Volume 18","author":"Riedel","year":"2005","journal-title":"Baylor University Medical Center Proceedings"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S0025727300000107","article-title":"Variolation, vaccination and popular resistance in early colonial south India","volume":"48","author":"Brimnes","year":"2004","journal-title":"Med. Hist."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105173","DOI":"10.1016\/j.actatropica.2019.105173","article-title":"An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines","volume":"200","author":"Mohebali","year":"2019","journal-title":"Acta Trop."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Foged, C., Rades, T., Perrie, Y., and Hook, S. (2015). Subunit Vaccine Delivery, Springer.","DOI":"10.1007\/978-1-4939-1417-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/311067a0","article-title":"Live recombinant vaccinia virus protects chimpanzees against hepatitis B","volume":"311","author":"Moss","year":"1984","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"16030","DOI":"10.1038\/mtm.2016.30","article-title":"Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens","volume":"3","author":"Afkhami","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Lorincz","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_11","unstructured":"WHO (2023, January 26). The Oxford\/AstraZeneca (ChAdOx1-S [Recombinant] Vaccine) COVID-19 Vaccine: What You Need to Know, Available online: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know."},{"key":"ref_12","unstructured":"WHO (2023, January 26). The Janssen Ad26.COV2.S COVID-19 Vaccine: What You Need to Know, Available online: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-j-j-covid-19-vaccine-what-you-need-to-know."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/nbt1207-1361","article-title":"Bridging the knowledge gaps in vaccine design","volume":"25","author":"Rappuoli","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102051","DOI":"10.1016\/j.parint.2020.102051","article-title":"Schistosomiasis and hookworm infection in humans: Disease burden, pathobiology and anthelmintic vaccines","volume":"75","author":"Anisuzzaman","year":"2020","journal-title":"Parasitol. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1098\/rstb.1997.0116","article-title":"Genetic analysis of host\u2013parasite coevolution in human malaria","volume":"352","author":"Liew","year":"1997","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1128\/CMR.15.4.595-612.2002","article-title":"History of human parasitology","volume":"15","author":"Cox","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-3024.2009.01141.x","article-title":"Viral vectors in malaria vaccine development","volume":"31","author":"Limbach","year":"2009","journal-title":"Parasite Immunol."},{"key":"ref_18","unstructured":"Bloom, B.R., and Lambert, P.-H. (2016). The Vaccine Book, Academic Press. [2nd ed.]."},{"key":"ref_19","unstructured":"WHO (2022, December 11). Neglected Tropical Diseases, Available online: https:\/\/www.who.int\/health-topics\/neglected-tropical-diseases."},{"key":"ref_20","unstructured":"WHO (2022, December 12). WHO Recommends Groundbreaking Malaria Vaccine for Children at Risk, Available online: https:\/\/www.who.int\/news\/item\/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"Gordon","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership (2015). Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet, 386, 31\u201345.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"ref_23","unstructured":"Maxmen, A. (2022, December 13). Scientists Hail Historic Malaria Vaccine Approval\u2014But Point to Challenges Ahead. Available online: https:\/\/www.nature.com\/articles\/d41586-021-02755-5#ref-CR1."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: A phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"46621","DOI":"10.1038\/srep46621","article-title":"Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine","volume":"7","author":"Collins","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fimmu.2020.00204","article-title":"The Delay in the Licensing of Protozoal Vaccines: A Comparative History","volume":"11","author":"Nico","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1017\/S0031182013002060","article-title":"Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs","volume":"141","author":"McAllister","year":"2014","journal-title":"Parasitology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fcimb.2018.00067","article-title":"Metazoan Parasite Vaccines: Present Status and Future Prospects","volume":"8","author":"Stutzer","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"711650","DOI":"10.3389\/fimmu.2021.711650","article-title":"Promising Technologies in the Field of Helminth Vaccines","volume":"12","author":"Perera","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_30","first-page":"001721","article-title":"ICTV Virus Taxonomy Profile: Adenoviridae 2022","volume":"103","author":"Aoki","year":"2022","journal-title":"J. Gen. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0036-1584923","article-title":"Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention","volume":"37","author":"Lynch","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1006\/mthe.2001.0329","article-title":"Acute Cytokine Response to Systemic Adenoviral Vectors in Mice Is Mediated by Dendritic Cells and Macrophages","volume":"3","author":"Zhang","year":"2001","journal-title":"Mol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2567.2006.02552.x","article-title":"Viral vector vaccines make memory T cells against malaria","volume":"121","author":"Harty","year":"2007","journal-title":"Immunology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors","volume":"10","author":"Kobinger","year":"2014","journal-title":"Hum. Vaccine Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1021\/acs.molpharmaceut.8b00591","article-title":"Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach","volume":"15","author":"Moreno","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eabl8213","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41541-022-00569-8","article-title":"Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination","volume":"7","author":"Buoninfante","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_40","unstructured":"WHO (2022, December 11). Status of COVID-19 Vaccines within WHO EUL\/PQ Evaluation Process, Available online: https:\/\/www.who.int\/teams\/regulation-prequalification\/eul\/covid-19."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.vaccine.2013.12.059","article-title":"Construction and evaluation of replication-defective recombinant optimized triosephosphate isomerase adenoviral vaccination in Schistosoma japonicum challenged mice","volume":"32","author":"Dai","year":"2014","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Dai, Y., Wang, X., Tang, J., Zhao, S., Xing, Y., Dai, J., Jin, X., and Zhu, Y. (2015). Enhancement of protective efficacy through adenoviral vectored vaccine priming and protein boosting strategy encoding triosephosphate isomerase (SjTPI) against Schistosoma japonicum in mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120792"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13071-017-2036-5","article-title":"Evaluation of protective efficacy induced by different heterologous prime-boost strategies encoding triosephosphate isomerase against Schistosoma japonicum in mice","volume":"10","author":"Dai","year":"2017","journal-title":"Parasites Vectors"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1007\/s00436-014-4104-5","article-title":"Evaluation of protective immune response in mice by vaccination the recombinant adenovirus for expressing Schistosoma japonicum inhibitor apoptosis protein","volume":"113","author":"Hu","year":"2014","journal-title":"Parasitol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"104036","DOI":"10.1016\/j.ebiom.2022.104036","article-title":"A low dose adenovirus vectored vaccine expressing Schistosoma mansoni Cathepsin B protects from intestinal schistosomiasis in mice","volume":"80","author":"Perera","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_46","unstructured":"WHO (2022). World Malaria Report 2022."},{"key":"ref_47","unstructured":"WHO (2022, December 11). Malaria, Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e12795","DOI":"10.1111\/pim.12795","article-title":"Immune responses to malaria pre-erythrocytic stages: Implications for vaccine development","volume":"43","author":"Abuga","year":"2021","journal-title":"Parasite Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1600-065X.2010.00988.x","article-title":"Cell biology and immunology of malaria","volume":"240","author":"Hafalla","year":"2011","journal-title":"Immunol. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/339409","article-title":"Protection of Humans against Malaria by Immunization with Radiation-Attenuated Plasmodium falciparum Sporozoites","volume":"185","author":"Hoffman","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.mib.2008.06.005","article-title":"Interactions of the malaria parasite and its mammalian host","volume":"11","author":"Silvie","year":"2008","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1021\/acs.jproteome.9b00324","article-title":"Proteomic Analysis of Plasmodium Merosomes: The Link between Liver and Blood Stages in Malaria","volume":"18","author":"Shears","year":"2019","journal-title":"J. Proteome Res."},{"key":"ref_53","unstructured":"Bloom, B.R., and Lambert, P.-H. (2003). The Vaccine Book, Academic Press."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"286re5","DOI":"10.1126\/scitranslmed.aaa2373","article-title":"Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults","volume":"7","author":"Ogwang","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mensah, V.A., Gueye, A., Ndiaye, M., Edwards, N.J., Wright, D., Anagnostou, N.A., Syll, M., Ndaw, A., Abiola, A., and Bliss, C. (2016). Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167951"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jiw244","article-title":"Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S\/AS01B with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP","volume":"214","author":"Rampling","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/mt.2016.83","article-title":"Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants","volume":"24","author":"Afolabi","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3389\/fimmu.2017.01551","article-title":"Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial","volume":"8","author":"Mensah","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1016\/j.vaccine.2017.09.028","article-title":"Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M\u2122","volume":"35","author":"Venkatraman","year":"2017","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Tiono, A.B., N\u00e9bi\u00e9, I., Anagnostou, N., Coulibaly, A.S., Bowyer, G., Lam, E., Bougouma, E.C., Ouedraogo, A., Yaro, J.B.B., and Barry, A. (2018). First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0208328"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41541-018-0084-2","article-title":"Safety and efficacy of novel malaria vaccine regimens of RTS,S\/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP","volume":"3","author":"Rampling","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1038\/s41598-018-21630-4","article-title":"Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP","volume":"8","author":"Bliss","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.4049\/jimmunol.1201455","article-title":"Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection","volume":"190","author":"Elias","year":"2013","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ogwang, C., Afolabi, M., Kimani, D., Jagne, Y.J., Sheehy, S.H., Bliss, C.M., Duncan, C.J., Collins, K.A., Garcia Knight, M.A., and Kimani, E. (2013). Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057726"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/IAI.01187-13","article-title":"Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites","volume":"82","author":"Bauza","year":"2014","journal-title":"Infect. Immun."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Biswas, S., Choudhary, P., Elias, S.C., Miura, K., Milne, K.H., de Cassan, S.C., Collins, K.A., Halstead, F.D., Bliss, C.M., and Ewer, K.J. (2014). Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107903"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"de Barra, E., Hodgson, S.H., Ewer, K.J., Bliss, C.M., Hennigan, K., Collins, A., Berrie, E., Lawrie, A.M., Gilbert, S.C., and Nicosia, A. (2014). A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115161"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/imm.12226","article-title":"Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection","volume":"141","author":"Elias","year":"2014","journal-title":"Immunology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1038\/mt.2014.109","article-title":"Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations","volume":"22","author":"Kimani","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/mt.2014.157","article-title":"Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: Report on a phase 1a clinical trial","volume":"22","author":"Hodgson","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Spencer, A.J., Cottingham, M.G., Jenks, J.A., Longley, R.J., Capone, S., Colloca, S., Folgori, A., Cortese, R., Nicosia, A., and Bregu, M. (2014). Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class II invariant chain. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100538"},{"key":"ref_74","first-page":"348","article-title":"Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax","volume":"6","author":"Shakri","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/IAI.01063-15","article-title":"Tailoring a Combination Preerythrocytic Malaria Vaccine","volume":"84","author":"Bauza","year":"2015","journal-title":"Infect. Immun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.chom.2014.11.017","article-title":"A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys","volume":"17","author":"Douglas","year":"2015","journal-title":"Cell Host Microbe"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1016\/j.vaccine.2015.09.094","article-title":"Progress with viral vectored malaria vaccines: A multi-stage approach involving \u201cunnatural immunity\u201d","volume":"33","author":"Ewer","year":"2015","journal-title":"Vaccine"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Longley, R.J., Halbroth, B.R., Ewer, K.J., Hill, A.V., and Spencer, A.J. (2015). Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144515"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1016\/j.vaccine.2015.03.039","article-title":"Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine","volume":"33","author":"Pearson","year":"2015","journal-title":"Vaccine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: From immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"18848","DOI":"10.1038\/srep18848","article-title":"Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ymthe.2016.11.003","article-title":"Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants","volume":"25","author":"Bliss","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7284","DOI":"10.1038\/s41598-017-07246-0","article-title":"Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria","volume":"7","author":"Milicic","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e00641-16","DOI":"10.1128\/IAI.00641-16","article-title":"Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine","volume":"85","author":"Longley","year":"2017","journal-title":"Infect. Immun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e93683","DOI":"10.1172\/jci.insight.93683","article-title":"Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies","volume":"2","author":"Payne","year":"2017","journal-title":"JCI Insight"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e96381","DOI":"10.1172\/jci.insight.96381","article-title":"Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions","volume":"2","author":"Payne","year":"2017","journal-title":"JCI Insight"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3389\/fimmu.2018.01660","article-title":"CXCR3(+) T Follicular Helper Cells Induced by Co-Administration of RTS,S\/AS01B and Viral-Vectored Vaccines Are Associated with Reduced Immunogenicity and Efficacy Against Malaria","volume":"9","author":"Bowyer","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e00573-19","DOI":"10.1128\/IAI.00573-19","article-title":"Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria","volume":"88","author":"Halbroth","year":"2020","journal-title":"Infect. Immun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"694759","DOI":"10.3389\/fimmu.2021.694759","article-title":"Safety and Immunogenicity of ChAd63\/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial","volume":"12","author":"Payne","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"11820","DOI":"10.1038\/srep11820","article-title":"Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates","volume":"5","author":"Longley","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"612910","DOI":"10.3389\/fimmu.2021.612910","article-title":"Liver-Directed AAV8 Booster Vaccine Expressing Plasmodium falciparum Antigen Following Adenovirus Vaccine Priming Elicits Sterile Protection in a Murine Model","volume":"12","author":"Shahnaij","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1016\/j.vaccine.2017.10.066","article-title":"A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII","volume":"35","author":"Shiratsuchi","year":"2017","journal-title":"Vaccine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12936-017-1896-7","article-title":"New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission","volume":"16","author":"McGuire","year":"2017","journal-title":"Malar. J."},{"key":"ref_94","unstructured":"PAHO (2022, December 11). Chagas Disease. Available online: https:\/\/www.paho.org\/en\/topics\/chagas-disease."},{"key":"ref_95","unstructured":"WHO (2022, December 11). Chagas Disease (American Trypanosomiasis), Available online: https:\/\/www.who.int\/health-topics\/chagas-disease."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2307\/3279787","article-title":"Tissue Tropism of Different Trypanosoma cruzi Strains","volume":"64","author":"Melo","year":"1978","journal-title":"J. Parasitol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1086\/314889","article-title":"Parasite Persistence Correlates with Disease Severity and Localization in Chronic Chagas\u2019 Disease","volume":"180","author":"Zhang","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4269\/ajtmh.2001.65.152","article-title":"Mouse model for Chagas disease: Immunohistochemical distribution of different stages of Trypanosoma cruzi in tissues throughout infection","volume":"65","author":"Guarner","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2613.2006.00476.x","article-title":"Trypanosoma cruzi: Clones isolated from the Colombian strain, reproduce the parental strain characteristics, with ubiquitous histotropism","volume":"87","author":"Camandaroba","year":"2006","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e12786","DOI":"10.1111\/pim.12786","article-title":"Host-parasite dynamics in Chagas disease from systemic to hyper-local scales","volume":"43","author":"Ward","year":"2021","journal-title":"Parasite Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.4049\/jimmunol.177.6.3515","article-title":"Cutting Edge: TLR9 and TLR2 Signaling Together Account for MyD88-Dependent Control of Parasitemia in Trypanosoma cruzi Infection","volume":"177","author":"Bafica","year":"2006","journal-title":"J. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.4049\/jimmunol.0800621","article-title":"Trypanosoma cruzi Triggers an Early Type I IFN Response In Vivo at the Site of Intradermal Infection","volume":"182","author":"Chessler","year":"2009","journal-title":"J. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fcimb.2019.00435","article-title":"Redox Balance Keepers and Possible Cell Functions Managed by Redox Homeostasis in Trypanosoma cruzi","volume":"9","author":"Garg","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4049\/jimmunol.0901178","article-title":"Insufficient TLR Activation Contributes to the Slow Development of CD8+ T Cell Responses in Trypanosoma cruzi Infection","volume":"183","author":"Padilla","year":"2009","journal-title":"J. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.4049\/jimmunol.158.7.3311","article-title":"IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi","volume":"158","author":"Hunter","year":"1997","journal-title":"J. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"165658","DOI":"10.1016\/j.bbadis.2019.165658","article-title":"Chagas disease vaccine design: The search for an efficient Trypanosoma cruzi immune-mediated control","volume":"1866","author":"Bivona","year":"2020","journal-title":"Biochim. Biophys. Acta BBA Mol. Basis Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1089\/hum.2006.17.898","article-title":"Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase","volume":"17","author":"Machado","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1128\/IAI.01459-08","article-title":"Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination","volume":"77","author":"Persechini","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1016\/j.vaccine.2009.07.013","article-title":"Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection","volume":"27","author":"Haolla","year":"2009","journal-title":"Vaccine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/IAI.01190-10","article-title":"Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi","volume":"79","author":"Rigato","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Dominguez, M.R., Silveira, E.L., de Vasconcelos, J.R., de Alencar, B.C., Machado, A.V., Bruna-Romero, O., Gazzinelli, R.T., and Rodrigues, M.M. (2011). Subdominant\/cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022011"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2012.02.037","article-title":"Re-circulation of lymphocytes mediated by sphingosine-1-phosphate receptor-1 contributes to resistance against experimental infection with the protozoan parasite Trypanosoma cruzi","volume":"30","author":"Dominguez","year":"2012","journal-title":"Vaccine"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Vasconcelos, J.R., Bru\u00f1a-Romero, O., Ara\u00fajo, A.F., Dominguez, M.R., Ersching, J., de Alencar, B.C., Machado, A.V., Gazzinelli, R.T., Bortoluci, K.R., and Amarante-Mendes, G.P. (2012). Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: Reversal by adenoviral vaccine. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002699"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/hum.2013.218","article-title":"Adenovirus vector-induced CD8\u207a T effector memory cell differentiation and recirculation, but not proliferation, are important for protective immunity against experimental Trypanosoma cruzi Infection","volume":"25","author":"Vasconcelos","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_115","first-page":"605023","article-title":"Genetic vaccination against experimental infection with myotropic parasite strains of Trypanosoma cruzi","volume":"2014","author":"Vasconcelos","year":"2014","journal-title":"Mediators Inflamm."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Pereira, I.R., Vilar-Pereira, G., Marques, V., da Silva, A.A., Caetano, B., Moreira, O.C., Machado, A.V., Bruna-Romero, O., Rodrigues, M.M., and Gazzinelli, R.T. (2015). A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004594"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3389\/fimmu.2017.01291","article-title":"LFA-1 Mediates Cytotoxicity and Tissue Migration of Specific CD8(+) T Cells after Heterologous Prime-Boost Vaccination against Trypanosoma cruzi Infection","volume":"8","author":"Ferreira","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Pontes Ferreira, C., Cariste, L.M., Ferri Moraschi, B., Ferrarini Zanetti, B., Won Han, S., Araki Ribeiro, D., Vieira Machado, A., Lannes-Vieira, J., Gazzinelli, R.T., and Vasconcelos, J.R.C. (2019). CXCR3 chemokine receptor guides Trypanosoma cruzi-specific T-cells triggered by DNA\/adenovirus ASP2 vaccine to heart tissue after challenge. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007597"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cyto.2018.07.017","article-title":"Therapeutic effects of vaccine derived from amastigote surface protein-2 (ASP-2) against Chagas disease in mouse liver","volume":"113","author":"Ribeiro","year":"2019","journal-title":"Cytokine"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Barbosa, R.P., Filho, B.G., Dos Santos, L.I., Junior, P.A., Marques, P.E., Pereira, R.V., Cara, D.C., Bru\u00f1a-Romero, O., Rodrigues, M.M., and Gazzinelli, R.T. (2013). Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061795"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Jovicic, N., Jeftic, I., Jovanovic, I., Radosavljevic, G., Arsenijevic, N., Lukic, M.L., and Pejnovic, N. (2015). Differential Immunometabolic Phenotype in Th1 and Th2 Dominant Mouse Strains in Response to High-Fat Feeding. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134089"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1002\/jcb.27608","article-title":"Therapeutical effects of vaccine from Trypanosoma cruzi amastigote surface protein 2 by simultaneous inoculation with live parasites","volume":"120","author":"Ribeiro","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cyto.2010.06.011","article-title":"Interleukin-12 as an adjuvant for induction of protective antibody responses","volume":"52","author":"Metzger","year":"2010","journal-title":"Cytokine"},{"key":"ref_125","unstructured":"O\u2019Hagan, D.T. (2000). Vaccine Adjuvants: Preparation Methods and Research Protocols, Springer."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nri1329","article-title":"Immunotherapeutic uses of CpG oligodeoxynucleotides","volume":"4","author":"Klinman","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14712598.2011.573624","article-title":"Role of AS04 in human papillomavirus vaccine: Mode of action and clinical profile","volume":"11","author":"Wettendorff","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.it.2010.08.005","article-title":"Educating CD4 T cells with vaccine adjuvants: Lessons from lipopolysaccharide","volume":"31","author":"McAleer","year":"2010","journal-title":"Trends Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1038\/emm.2017.172","article-title":"Bacterial flagellin\u2014A potent immunomodulatory agent","volume":"49","author":"Hajam","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: Helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1016\/j.vaccine.2018.05.029","article-title":"The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway","volume":"36","author":"Jain","year":"2018","journal-title":"Vaccine"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59\u00ae adjuvant: A phoenix that arose from the ashes","volume":"12","author":"Ott","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/vaccines3030579","article-title":"Cholera Toxin Subunit B as Adjuvant\u2013\u2013An Accelerator in Protective Immunity and a Break in Autoimmunity","volume":"3","author":"Stratmann","year":"2015","journal-title":"Vaccines"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e00215","DOI":"10.1128\/mSphere.00215-18","article-title":"The Mucosal Vaccine Adjuvant LT(R192G\/L211A) or dmLT","volume":"3","author":"Clements","year":"2018","journal-title":"mSphere"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Farrow, A.L., Rachakonda, G., Gu, L., Krendelchtchikova, V., Nde, P.N., Pratap, S., Lima, M.F., Villalta, F., and Matthews, Q.L. (2014). Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003089"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Farrow, A.L., Peng, B.J., Gu, L., Krendelchtchikov, A., and Matthews, Q.L. (2016). A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors. Viruses, 8.","DOI":"10.3390\/v8030078"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.20411\/pai.v1i2.114","article-title":"Epitope Capsid-Incorporation: New Effective Approach for Vaccine Development for Chagas Disease","volume":"1","author":"Matthews","year":"2016","journal-title":"Pathog. Immun."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(13)61949-2","article-title":"Human schistosomiasis","volume":"383","author":"Colley","year":"2014","journal-title":"Lancet"},{"key":"ref_142","unstructured":"WHO (2022, December 05). Schistosomiasis (Bilharzia), Available online: https:\/\/www.who.int\/health-topics\/schistosomiasis."},{"key":"ref_143","unstructured":"Centers for Disease Control and Prevention (2022, December 05). Schistosomiasis, Available online: https:\/\/www.cdc.gov\/parasites\/schistosomiasis\/."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00281-020-00789-x","article-title":"Schistosomiasis\u2014From immunopathology to vaccines","volume":"42","author":"McManus","year":"2020","journal-title":"Semin. Immunopathol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0140-6736(17)32130-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Hay","year":"2017","journal-title":"Lancet"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1093\/cid\/ciy001","article-title":"Are We on Our Way to Achieving the 2020 Goals for Schistosomiasis Morbidity Control Using Current World Health Organization Guidelines?","volume":"66","author":"Toor","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/pim.12087","article-title":"Immunology of human schistosomiasis","volume":"36","author":"Colley","year":"2014","journal-title":"Parasite Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Frahm, S., Anisuzzaman, A., Prodjinotho, U.F., Vejzagi\u0107, N., Verschoor, A., and Prazeres da Costa, C. (2019). A novel cell-free method to culture Schistosoma mansoni from cercariae to juvenile worm stages for in vitro drug testing. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0006590"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"635622","DOI":"10.3389\/fimmu.2021.635622","article-title":"Host-Specific Serum Factors Control the Development and Survival of Schistosoma mansoni","volume":"12","author":"Anisuzzaman","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_150","first-page":"119","article-title":"Current Understanding of Immunity against Schistosomiasis: Impact on Vaccine and Drug Development","volume":"11","author":"Molehin","year":"2020","journal-title":"Res. Rep. Trop. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.3389\/fimmu.2018.03042","article-title":"Schistosome Egg Migration: Mechanisms, Pathogenesis and Host Immune Responses","volume":"9","author":"Costain","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4269\/ajtmh.2007.77.676","article-title":"T regulatory cell levels decrease in people infected with Schistosoma mansoni on effective treatment","volume":"77","author":"Watanabe","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1286-4579(99)80093-8","article-title":"Strategies for a schistosome vaccine: Can we manipulate the immune response effectively?","volume":"1","author":"Wilson","year":"1999","journal-title":"Microbes Infect."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.4049\/jimmunol.164.12.6406","article-title":"IL-10 and the Dangers of Immune Polarization: Excessive Type 1 and Type 2 Cytokine Responses Induce Distinct Forms of Lethal Immunopathology in Murine Schistosomiasis","volume":"164","author":"Hoffmann","year":"2000","journal-title":"J. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Zhu, X., and Zhu, J. (2020). CD4 T Helper Cell Subsets and Related Human Immunological Disorders. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218011"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0014-4894(78)90040-1","article-title":"Schistosoma mansoni: Infectivity and immunizing effects of in vitro derived schistosomula attenuated by X irradiation","volume":"45","author":"Eveland","year":"1978","journal-title":"Exp. Parasitol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4269\/ajtmh.1978.27.76","article-title":"Immunization of Mice with Cobalt-60 Irradiated Schistosoma Mansoni Cercariae","volume":"27","author":"Minard","year":"1978","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"635985","DOI":"10.3389\/fimmu.2021.635985","article-title":"Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings","volume":"12","author":"Driciru","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jare.2014.10.002","article-title":"Why the radiation-attenuated cercarial immunization studies failed to guide the road for an effective schistosomiasis vaccine: A review","volume":"6","author":"Tallima","year":"2015","journal-title":"J. Adv. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4049\/jimmunol.163.2.927","article-title":"Studies with double cytokine-deficient mice reveal that highly polarized Th1- and Th2-type cytokine and antibody responses contribute equally to vaccine-induced immunity to Schistosoma mansoni","volume":"163","author":"Hoffmann","year":"1999","journal-title":"J. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Gray, D.J., Williams, G.M., Li, Y., and McManus, D.P. (2009). Transmission Dynamics of Schistosoma japonicum in the Lakes and Marshlands of China. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0004058"},{"key":"ref_162","first-page":"518","article-title":"The protective immunity of a DNA vaccine encoding Schistosoma japonicum Chinese strain triose-phosphate isomerase in infected BALB\/C mice","volume":"35","author":"Zhu","year":"2004","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1016\/j.vaccine.2016.07.033","article-title":"Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits","volume":"34","author":"Choudhry","year":"2016","journal-title":"Vaccine"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.vaccine.2015.12.032","article-title":"Workshop report: Schistosomiasis vaccine clinical development and product characteristics","volume":"34","author":"Mo","year":"2016","journal-title":"Vaccine"},{"key":"ref_165","unstructured":"WHO (2022, December 06). Leishmaniasis, Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(03)00517-6","article-title":"Post-kala-azar dermal leishmaniasis","volume":"3","author":"Zijlstra","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"ref_167","unstructured":"WHO (2022, December 06). Leishmaniasis, Available online: https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/indicator-groups\/indicator-group-details\/GHO\/leishmaniasis."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Akhoundi, M., Kuhls, K., Cannet, A., Vot\u00fdpka, J., Marty, P., Delaunay, P., and Sereno, D. (2016). A Historical Overview of the Classification, Evolution, and Dispersion of Leishmania Parasites and Sandflies. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004349"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev.iy.07.040189.003021","article-title":"T-cell Responses and Immunity to Experimental Infection with Leishmania major","volume":"7","author":"Pedrazzini","year":"1989","journal-title":"Annu. Rev. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/icb.1979.2","article-title":"Murine cutaneous leishmaniasis: Disease patterns in intact and nude mice of various genotypes and examination of some differences between normal and infected macrophages","volume":"57","author":"Handman","year":"1979","journal-title":"Aust. J. Exp. Biol. Med. Sci."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri933","article-title":"The immunology of susceptibility and resistance to Leishmania major in mice","volume":"2","author":"Sacks","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Costa-da-Silva, A.C., Nascimento, D.O., Ferreira, J.R.M., Guimar\u00e3es-Pinto, K., Freire-de-Lima, L., Morrot, A., Decote-Ricardo, D., Filardy, A.A., and Freire-de-Lima, C.G. (2022). Immune Responses in Leishmaniasis: An Overview. Trop. Med. Infect. Dis., 7.","DOI":"10.3390\/tropicalmed7040054"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/iai.26.2.611-614.1979","article-title":"Generalized infection and lack of delayed hypersensitivity in BALB\/c mice infected with Leishmania tropica major","volume":"26","author":"Nasseri","year":"1979","journal-title":"Infect. Immun."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1574-695X.2007.00311.x","article-title":"Immune response to leishmania: Paradox rather than paradigm","volume":"51","author":"Tripathi","year":"2007","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"624009","DOI":"10.3389\/fcimb.2021.624009","article-title":"Role of Cytokines in Experimental and Human Visceral Leishmaniasis","volume":"11","author":"Samant","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fimmu.2012.00005","article-title":"CD8+ T Cells in Leishmania Infections: Friends or Foes?","volume":"3","author":"Stager","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.0141-9838.2004.00672.x","article-title":"CD8+ T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis","volume":"25","author":"Tsagozis","year":"2003","journal-title":"Parasite Immunol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0065-308X(08)60022-6","article-title":"The Interaction of Leishmania Species with Macrophages","volume":"Volume 31","author":"Baker","year":"1992","journal-title":"Advances in Parasitology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/375408a0","article-title":"Altered immune responses in mice lacking inducible nitric oxide synthase","volume":"375","author":"Wei","year":"1995","journal-title":"Nature"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Carneiro, P.P., Concei\u00e7\u00e3o, J., Macedo, M., Magalh\u00e3es, V., Carvalho, E.M., and Bacellar, O. (2016). The Role of Nitric Oxide and Reactive Oxygen Species in the Killing of Leishmania braziliensis by Monocytes from Patients with Cutaneous Leishmaniasis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148084"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Carstens-Kass, J., Paulini, K., Lypaczewski, P., and Matlashewski, G. (2021). A review of the leishmanin skin test: A neglected test for a neglected disease. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009531"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"639801","DOI":"10.3389\/fcimb.2021.639801","article-title":"Revival of Leishmanization and Leishmanin","volume":"11","author":"Volpedo","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/ijpvm.IJPVM_116_18","article-title":"Leishmania Vaccines Entered in Clinical Trials: A Review of Literature","volume":"10","author":"Moafi","year":"2019","journal-title":"Int. J. Prev. Med."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Grimaldi, G., Teva, A., Porrozzi, R., Pinto, M.A., Marchevsky, R.S., Rocha, M.G., Dutra, M.S., Bru\u00f1a-Romero, O., Fernandes, A.P., and Gazzinelli, R.T. (2014). Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002853"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Osman, M., Mistry, A., Keding, A., Gabe, R., Cook, E., Forrester, S., Wiggins, R., Di Marco, S., Colloca, S., and Siani, L. (2017). A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005527"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ymthe.2021.03.020","article-title":"Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan","volume":"29","author":"Younis","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/tmi.13382","article-title":"Commercially approved vaccines for canine leishmaniosis: A review of available data on their safety and efficacy","volume":"25","author":"Velez","year":"2020","journal-title":"Trop. Med. Int. Health"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jir842","article-title":"Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis","volume":"205","author":"Maroof","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya","year":"2004","journal-title":"Lancet"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Flegr, J., Prandota, J., Sovi\u010dkov\u00e1, M., and Israili, Z.H. (2014). Toxoplasmosis\u2014A global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090203"},{"key":"ref_191","first-page":"898","article-title":"Global status of Toxoplasma gondii infection: Systematic review and prevalence snapshots","volume":"36","author":"Molan","year":"2019","journal-title":"Trop. Biomed."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","article-title":"Toxoplasma gondii: From animals to humans","volume":"30","author":"Tenter","year":"2000","journal-title":"Int. J. Parasitol."},{"key":"ref_193","unstructured":"Centers for Disease Control and Prevention (2022, December 10). Toxoplasmosis (Toxoplasma infection), Available online: https:\/\/www.cdc.gov\/parasites\/toxoplasmosis\/."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/jpids\/piu077","article-title":"Congenital Toxoplasmosis","volume":"3","author":"McAuley","year":"2014","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/CMR.05013-11","article-title":"Epidemiology of and diagnostic strategies for toxoplasmosis","volume":"25","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.pt.2020.08.005","article-title":"Toxoplasma gondii: An Underestimated Threat?","volume":"36","author":"Milne","year":"2020","journal-title":"Trends Parasitol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13071-022-05398-1","article-title":"The association between Toxoplasma infection and mortality: The NHANES epidemiologic follow-up study","volume":"15","author":"Huang","year":"2022","journal-title":"Parasites Vectors"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1645\/GE-2712.1","article-title":"A Review: Competence, Compromise, and Concomitance\u2014Reaction of the Host Cell To Toxoplasma gondii Infection and Development","volume":"97","author":"Peng","year":"2011","journal-title":"J. Parasitol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0353-9","article-title":"Innate, adaptive, and cell-autonomous immunity against Toxoplasma gondii infection","volume":"51","author":"Sasai","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"102226","DOI":"10.1016\/j.coi.2022.102226","article-title":"Immune responses to Toxoplasma gondii","volume":"77","author":"Khan","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41590-018-0250-8","article-title":"Alarmin S100A11 initiates a chemokine response to the human pathogen Toxoplasma gondii","volume":"20","author":"Safronova","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.chom.2012.12.003","article-title":"Combined Action of Nucleic Acid-Sensing Toll-like Receptors and TLR11\/TLR12 Heterodimers Imparts Resistance to Toxoplasma gondii in Mice","volume":"13","author":"Andrade","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1128\/iai.62.7.2818-2824.1994","article-title":"Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: Regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha","volume":"62","author":"Hunter","year":"1994","journal-title":"Infect. Immun."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/intimm\/dxy004","article-title":"Host immune responses to Toxoplasma gondii","volume":"30","author":"Sasai","year":"2018","journal-title":"Int. Immunol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"102030","DOI":"10.1016\/j.parint.2019.102030","article-title":"The immune system utilizes two distinct effector mechanisms of T cells depending on two different life cycle stages of a single pathogen, Toxoplasma gondii, to control its cerebral infection","volume":"76","author":"Suzuki","year":"2020","journal-title":"Parasitol. Int."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"9196","DOI":"10.1073\/pnas.1015298108","article-title":"Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1\u2013PDL-1 blockade","volume":"108","author":"Bhadra","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1084\/jem.20151995","article-title":"Blimp-1\u2013mediated CD4 T cell exhaustion causes CD8 T cell dysfunction during chronic toxoplasmosis","volume":"213","author":"Hwang","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Chu, K.B., and Quan, F.S. (2021). Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development. Vaccines, 9.","DOI":"10.3390\/vaccines9050413"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41541-022-00563-0","article-title":"Toxoplasmosis vaccines: What we have and where to go?","volume":"7","author":"Zhang","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1017\/S003118200000144X","article-title":"A commercial vaccine for ovine toxoplasmosis","volume":"110","author":"Buxton","year":"1995","journal-title":"Parasitology"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vetpar.2009.02.026","article-title":"Toxoplasmosis in sheep\u2014The last 20 years","volume":"163","author":"Dubey","year":"2009","journal-title":"Vet. Parasitol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/hum.2006.17.415","article-title":"Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice","volume":"17","author":"Caetano","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1016\/j.vaccine.2010.02.003","article-title":"Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity","volume":"28","author":"Machado","year":"2010","journal-title":"Vaccine"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1016\/j.vaccine.2011.04.044","article-title":"MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8+ T lymphocytes","volume":"29","author":"Mendes","year":"2011","journal-title":"Vaccine"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Mendes, \u00c9.A., Fonseca, F.G., Cas\u00e9rio, B.M., Colina, J.P., Gazzinelli, R.T., and Caetano, B.C. (2013). Recombinant vaccines against T. gondii: Comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063201"},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Li, X.Z., Wang, X.H., Xia, L.J., Weng, Y.B., Hernandez, J.A., Tu, L.Q., Li, L.T., Li, S.J., and Yuan, Z.G. (2015). Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0815-1"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.meegid.2016.10.006","article-title":"Recombinant canine adenovirus type-2 expressing TgROP16 provides partial protection against acute Toxoplasma gondii infection in mice","volume":"45","author":"Li","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Sklar, M.J., Maiolatesi, S., Patterson, N., Sedegah, M., Limbach, K., Teneza-Mora, N., Chuang, I., Hollis-Perry, K.M., Banania, J.G., and Guzman, I. (2021). A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-na\u00efve adults. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0256980"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/s13071-015-1108-7","article-title":"A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB\/c mice against parasite infection","volume":"8","author":"Yin","year":"2015","journal-title":"Parasites Vectors"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1051\/parasite\/2017013","article-title":"Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes","volume":"24","author":"Wang","year":"2017","journal-title":"Parasite"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines\u2014Fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.vaccine.2018.12.044","article-title":"Vaccination with recombinant adenoviruses expressing Toxoplasma gondii MIC3, ROP9, and SAG2 provide protective immunity against acute toxoplasmosis in mice","volume":"37","author":"Zhang","year":"2019","journal-title":"Vaccine"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fmicb.2017.00216","article-title":"Immuno-Efficacy of a T. gondii Secreted Protein with an Altered Thrombospondin Repeat (TgSPATR) As a Novel DNA Vaccine Candidate against Acute Toxoplasmosis in BALB\/c Mice","volume":"8","author":"Zheng","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_224","first-page":"1269","article-title":"Newly recognized fatal protozoan disease of dogs","volume":"192","author":"Dubey","year":"1988","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1128\/CMR.00031-06","article-title":"Epidemiology and control of neosporosis and Neospora caninum","volume":"20","author":"Dubey","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_226","first-page":"236","article-title":"Experimental fetal and transplacental Neospora infection in the nonhuman primate","volume":"71","author":"Barr","year":"1994","journal-title":"Lab. Investig."},{"key":"ref_227","first-page":"235","article-title":"Construction of an Adenovirus Vaccine Expressing the Cross-reactive Antigen AMA1 for Neospora caninum and Toxoplasma gondii and Its Immune Response in an Animal Model","volume":"13","author":"Jia","year":"2018","journal-title":"Iran. J. Parasitol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.exppara.2010.05.008","article-title":"Regulation of CD8+ T cell responses to infection with parasitic protozoa","volume":"126","author":"Jordan","year":"2010","journal-title":"Exp. Parasitol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1365-3024.1997.d01-200.x","article-title":"Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep","volume":"19","author":"Rothel","year":"1997","journal-title":"Parasite Immunol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2307\/3284533","article-title":"Shift from an early protective Th1-type immune response to a late permissive Th2-type response in murine cysticercosis (Taenia crassiceps)","volume":"84","author":"Terrazas","year":"1998","journal-title":"J. Parasitol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/pim.12351","article-title":"Host Th1\/Th2 immune response to Taenia solium cyst antigens in relation to cyst burden of neurocysticercosis","volume":"38","author":"Tharmalingam","year":"2016","journal-title":"Parasite Immunol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4161\/hv.6.1.10116","article-title":"Prime-boost vectored malaria vaccines: Progress and prospects","volume":"6","author":"Hill","year":"2010","journal-title":"Hum. Vaccine"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14760584.2016.1228454","article-title":"Development of replication-deficient adenovirus malaria vaccines","volume":"16","author":"Hollingdale","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Pance, A. (2020). Diversify and Conquer: The Vaccine Escapism of Plasmodium falciparum. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111748"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/3\/334\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:39:09Z","timestamp":1760121549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/3\/334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":236,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ph16030334"],"URL":"https:\/\/doi.org\/10.3390\/ph16030334","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]}}}